AmirAli Talasaz

AmirAli Talasaz is a prominent figure in the biotechnology sector, serving as the Co-founder and Co-Chief Executive Officer of Guardant Health, a company specializing in cancer detection through advanced blood tests. His leadership has been instrumental in the development of innovative technologies aimed at revolutionizing cancer care.

Professional Background

• Guardant Health: Talasaz co-founded Guardant Health in 2012 and has held various leadership roles, including President and Chairman until August 2021. Under his guidance, the company has made significant strides in liquid biopsy technology, which allows for non-invasive cancer detection and monitoring.
• Illumina: Prior to his work at Guardant Health, Talasaz was involved with Illumina, where he served as Senior Director of Scientific Research and previously as Director of Scientific Research from 2009 to 2012. His work there focused on genomic technologies that are foundational to modern genetic testing.
• Auriphex Biosciences: He co-founded this company in 2008, contributing to the field of molecular diagnostics.
• Stanford Genome Technology Center: Talasaz worked as an Engineering Research Associate and Technology Lead from 2007 to 2009, further solidifying his expertise in genomic research.

Education

AmirAli Talasaz earned his education at Stanford University, where he developed a strong foundation in scientific research and technology.

Current Focus

As Co-CEO of Guardant Health, Talasaz is committed to advancing cancer diagnostics through innovative solutions such as the Shield blood test, which aims to detect early signs of colorectal cancer in average-risk adults. His vision continues to drive the company's mission to improve patient outcomes through early detection and personalized treatment options.

Talasaz is based in the San Francisco Bay Area and maintains an active presence on LinkedIn, where he engages with the broader scientific community and shares updates about advancements at Guardant Health.